ArticleFrontiers in microbiology2025
Comparative and clinical impact of targeted next-generation sequencing in pediatric pneumonia diagnosis and treatment.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Early targeted next-generation sequencing accelerates clinical recovery in children with community-acquired pneumonia: A retrospective study.Pakistan journal of medical sciences · 2026Article
- Targeted next-generation sequencing for pediatric community-acquired pneumonia pathogen detection: a single-center study.Frontiers in cellular and infection microbiology · 2026Article
- Targeted next-generation sequencing analysis of pathogens and microecology in pediatric lower respiratory tract infections identifies risk factors for severe community-acquired pneumonia.Frontiers in cellular and infection microbiology · 2026Article
- Non-invasive molecular surveillance of drug-resistant bacterial and fungal pathogens in severe ICU pneumonia: a comparative study of nasopharyngeal swabs and BALF.Frontiers in microbiology · 2026Article
- Decoding pulmonary infections through targeted next-generation sequencing: comprehensive pathogen profiling in 999 clinical cases.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Community-acquired pneumonia (CAP) remains a significant cause of pediatric morbidity and mortality worldwide. Conventional microbial tests (CMTs) frequently fail to accurately identify pathogens, especially in cases involving co-infections or less common organisms. Targeted next-generation sequencing (tNGS) presents a promising alternative, offering comprehensive pathogen detection. Methods: A retrospective observational analysis was conducted on 206 pediatric CAP patients from July 2021 to January 2023. Bronchoalveolar lavage fluid (BALF) samples underwent simultaneous tNGS and CMTs. Clinical diagnoses based on comprehensive analysis served as the reference standard. Relative abundance thresholds were optimized to reduce false-positive detections. Results: Targeted next-generation sequencing detected pathogens in 97.0% (200/206) of cases, significantly higher than CMTs (52.9%, 109/206; Conclusion: Targeted next-generation sequencing provides significantly improved pathogen detection, especially for co-infections, compared to CMTs. Implementing standardized relative abundance thresholds enhances the diagnostic specificity of tNGS, supporting its integration into routine clinical diagnostics for pediatric CAP to facilitate precise, timely therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.